Amycolatopsis mediterranei: A Sixty-Year Journey from Strain Isolation to Unlocking Its Potential of Rifamycin Analogue Production by Combinatorial Biosynthesis

• Published in: Journal of natural products (Washington, D.C.) D.C.), 2024-02, Vol.87 (2), p.424-438
• Main Authors: Sood, Utkarsh, Müller, Moritz, Lan, Tian, Garg, Gauri, Singhvi, Nirjara, Hira, Princy, Singh, Priya, Nigam, Aeshna, Verma, Mansi, Lata, Pushp, Kaur, Hardeep, Kumar, Abhilash, Rawat, Charu Dogra, Lal, Sukanya, Aldrich, Courtney, Bechthold, Andreas, Lal, Rup
• Format: Article
• Language: English
• Subjects: Actinomycetales; Amycolatopsis; Biosynthetic Pathways - genetics; Rifamycins - metabolism
• ISSN: 0163-3864; 1520-6025
• DOI: 10.1021/acs.jnatprod.3c00686

Ever since the isolation of Amycolatopsis mediterranei in 1957, this strain has been the focus of research worldwide. In the last 60 years or more, our understanding of the taxonomy, development of cloning vectors and conjugation system, physiology, genetics, genomics, and biosynthetic pathway of rifamycin B production in A. mediterranei has substantially increased. In particular, the development of cloning vectors, transformation system, characterization of the rifamycin biosynthetic gene cluster, and the regulation of rifamycin B production by the pioneering work of Heinz Floss have made the rifamycin polyketide biosynthetic gene cluster (PKS) an attractive target for extensive genetic manipulations to produce rifamycin B analogues which could be effective against multi-drug-resistant tuberculosis. Additionally, a better understanding of the regulation of rifamycin B production and the application of newer genomics tools, including CRISPR-assisted genome editing systems, might prove useful to overcome the limitations associated with low production of rifamycin analogues.